<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To evaluate efficacy of low-molecular <z:chebi fb="5" ids="28304">heparin</z:chebi> enoxaparin in the treatment of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in patients with primary and <z:e sem="disease" ids="C0409983" disease_type="Disease or Syndrome" abbrv="">secondary antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: A total of 11 APS-<z:hpo ids='HP_0000112'>nephropathy</z:hpo> patients participated in the study </plain></SENT>
<SENT sid="2" pm="."><plain>Of them 8 patients had primary APS and 3 patients had secondary APS </plain></SENT>
<SENT sid="3" pm="."><plain>Biopsy of the kidney was made in 5 patients, ultrasonic dopplerography of renal vessels was performed in <z:hpo ids='HP_0000001'>all</z:hpo> 11 patients </plain></SENT>
<SENT sid="4" pm="."><plain>Enoxaparin was given as monotherapy to primary APS and combined treatment to secondary APS patients </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Enoxaparin decreased <z:hpo ids='HP_0000093'>proteinuria</z:hpo>, arterial pressure, glomerular filtration rate in <z:hpo ids='HP_0000001'>all</z:hpo> the patients </plain></SENT>
<SENT sid="6" pm="."><plain>It also promoted normalization of creatinin </plain></SENT>
<SENT sid="7" pm="."><plain>Before the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> treatment a reduction of maximal systolic and diastolic velocities of blood flow have been registered in segmental and interlobar arteries in <z:hpo ids='HP_0000001'>all</z:hpo> APS <z:hpo ids='HP_0000112'>nephropathy</z:hpo> patients compared to healthy subjects </plain></SENT>
<SENT sid="8" pm="."><plain>The <z:mpath ids='MPATH_63'>depletion</z:mpath> of renal cortex blood flow beginning with the level of arcuate arteries was also observed in <z:hpo ids='HP_0000001'>all</z:hpo> the patients </plain></SENT>
<SENT sid="9" pm="."><plain>Enoxaparin enhanced blood flow in segmental and interlobar arteries </plain></SENT>
<SENT sid="10" pm="."><plain>The recovery of blood flow in the arcuate arteries was registered in 6 of 9 patients </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Low molecular <z:chebi fb="5" ids="28304">heparin</z:chebi> may be used in the treatment of <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in patients with primary and secondary APS </plain></SENT>
</text></document>